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Purpose: To identify, map, and synthesize the individual-level key associations and modes of exposure
for hepatitis C virus (HCV) infection in the Middle East and North Africa (MENA), the most affected region
by HCV.
Methods: Source of data was the MENA HCV Epidemiology Synthesis Project database, populated
through systematic literature searches. Risk factors determined to be statistically signiﬁcant after
adjustment for confounders were extracted and categorized into key associations or modes of exposure.
Results: In total, 329 risk factors were identiﬁed from 109 articles in 14 of 24 MENA countries. Among key
associations, age was most frequently reported (n ¼ 39; 34.2%), followed by other infections/diseases
(n ¼ 20; 17.5%), and incarceration (n ¼ 17; 14.9%). Among modes of exposure, health careerelated
exposures were most frequently reported (n ¼ 127; 59.5%), followed by injecting drug use exposures
(n ¼ 45; 20.9%), community-related exposures (n ¼ 34; 15.8%), and sexual-related exposures (n ¼ 8;
3.7%). Blood transfusion, hemodialysis, surgical and other medical procedures, dental work, and medical
injections were identiﬁed as key health careerelated exposures.
Conclusions: Health care appears to be the primary driver of prevalent (and possibly incident) infections
in MENA, followed by injecting drug use. HCV screening should target the identiﬁed modes of exposure.
Commitment to prevention should be an integral component of HCV response to achieve HCV elimi-
nation by 2030, with focus on strengthening infection control in health care facilities, improving in-
jection safety and blood screening, and expanding harm reduction services for people who inject drugs.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen and a cause of
several morbidities, such as liver ﬁbrosis, cirrhosis, and cancer [1].
With a global estimate of 62e79 million people being chronically
infected [2], HCV-related morbidity and mortality place a burden
on health care systems worldwide [3]. The Middle East and North
Africa (MENA) region is the most affected by HCV, with over 15
million chronically infected individuals [2,4].
A series of systematic reviews and meta-analyses were con-
ducted recently to characterize HCV epidemiology in MENA [5e14].
Varying HCV prevalence in the general population was observed
across MENA countries. Countries with the highest HCV prevalence
were Egypt at 11.9% [6] and Pakistan at 6.2% [14]. For the remaining
countries, HCV prevalence was comparable to global levels, ranging
from 0.2% in Iraq, Lebanon, and Palestine [9], to 1.9% in Yemen [10].
HCV genotype distribution and its regional trends were also
delineated [15,16]. HCV viremic rate, that is, the proportion of HCV
chronically infected individuals of all ever-infected individuals, was
also recently assessed [17]. Two-thirds of HCV antibody-positive
individuals in MENA were found chronically infected and in need
of treatment [17]. The systematic reviews conducted quality as-
sessments of included HCV studies, and existing evidence was
found to be of reasonable quality [5e14]. The diagnostic tests used
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were also overall of quality, with most studies using the more
sensitive and speciﬁc third- or fourth-generation assays for HCV
antibody detection, with many studies using conﬁrmatory tests
also [5e14].
The recent development of the highly efﬁcacious direct-acting
antivirals provides avenues for achieving major reductions in HCV
infection and disease burden [18,19]. As such, a global target has
been set to eliminate HCV as a public health concern by 2030
[20,21]. However, screening those chronically infected and
ensuring access to treatment remainmajor challenges acrossMENA
[22,23]. Prevention of new HCV infections is also integral to
achieving elimination by 2030 [21].
The key associations and modes of exposures for HCV infection
vary across regions and countries [24e26]. For example, health
careerelated exposures appears to be an important mode of
exposure in low- and middle-income countries; however, it is no
longer a major mode of exposure in many developed countries
[24e26]dsuch as the United States where most exposures appear
to be related to injecting drug use [26,27]. This highlights the need
to identify, for each region or country, the speciﬁc modes of
exposures for HCV infection to inform HCV response and progress
toward HCV elimination by 2030.
Against this background, the speciﬁc aim of our study is to
delineate and map, through comprehensive systematic searches of
HCV literature in MENA, the individual-level key associations and
modes of exposure for HCV infection. The overarching goals of our
study are to inform HCV prevention by identifying the modes of
exposures and settings of vulnerability for this infection and to
inform the development of cost-effective screening strategies that
can identify infected individuals with a high yield. To our knowl-
edge, this is the ﬁrst systematic synthesis for any world region of
HCV key associations and modes of exposure.
This work was conducted as part of the MENA HCV Epidemi-
ology Synthesis Projectdan ongoing effort to describe and under-
stand HCV epidemiology and to inform key public health research,
resource allocation, policy, and programming priorities in the
region [5e15,17,28e31].
Methods
Data sources
The source of data for our study was the MENA HCV Epidemi-
ology Synthesis Project database, a comprehensive database of HCV
epidemiological measures in MENA [5e14]. The database consists
of several subdatabases of studies for different outcomes, such as
HCV antibody prevalence subdatabase comprised of 2543 antibody
prevalence studies among 51,598,736 participants, ribonucleic acid
prevalence (among antibody-positive persons) subdatabase
comprised of 178 ribonucleic acid prevalence studies among 19,593
HCV antibody-positive participants, and genotype frequency sub-
database comprised of 338 HCV genotype studies among 82,257
participants. The database also includes a subdatabase of
individual-level HCV risk factors including 329 risk factors identi-
ﬁed from 109 studies. The latter subdatabase is the focus of our
analyses in the present article. The MENA HCV Epidemiology
Synthesis Project database was constructed through a series of
systematic reviews for HCV infection across MENA [5e14].
Systematic reviews: overview
The systematic reviews were informed by the Cochrane
Collaboration Handbook [32] and reported their ﬁndings using
the Preferred Reporting Items for Systematic Reviews and
Meta-analyses guidelines [33]. The Preferred Reporting Items for
Systematic Reviews and Meta-analyses ﬂow diagrams describing
the selection process by which studies were included can be found
in the respective systematic reviews [5e14]. Reviewed evidence
included peer-reviewed publications identiﬁed through interna-
tional scientiﬁc databases (PubMed and Embase), regional-and
country-level scientiﬁc databases, MENA HIV/AIDS Epidemiology
Synthesis Project database [34,35], abstract archives of nonindexed
international conferences, and gray literature comprised of public
health reports and routine data reporting.
Broad search criteria were used in these reviews combining
medical index terms exploded to cover all subheadings and free
text terms for HCV and country names, to ensure inclusiveness. No
language restrictions were used as non-English articles were
extracted by native speakers. Screening of articles was restricted to
those published after 1989, the year inwhich HCV was identiﬁed as
a virus for the ﬁrst time [36,37].
Inclusion and exclusion criteria
The systematic reviews used the same inclusion and exclusion
criteria adapted for the subregion or country of interest [5e14]. The
speciﬁc inclusion and exclusion criteria can be found in detail in the
respective systematic reviews [5e14]. Brieﬂy, all studies included in
the reviews qualiﬁed for inclusion if they reported HCV antibody
incidence and/or antibody prevalence based on biological assays
and on primary data, in any population, in Afghanistan, Algeria,
Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya,
Mauritania, Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Ara-
bia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates, or
Yemen. Studies had to have a minimum sample size of 25. The
exclusion criteria encompassed case reports, case series, editorials,
letters to editors, commentaries, literature reviews, and studies
reporting HCV prevalence based on self-reporting. Studies referring
to HCV as non-A non-B hepatitis, or were performed before 1989,
were also excluded.
Extraction of risk factors and conceptual mapping
These systematic searches identiﬁed studies that assessed
individual-level risk factors for incident HCV infection (in pro-
spective or retrospective incidence studies) or individual-level
factors associated with being infected with HCV infection (in
cross-sectional studies of prevalent HCV infections). While these
two types of factors are technically different and have been derived
using different epidemiologic study designs, our focus in the pre-
sent study is to identify factors that are predictive of HCV infection,
whether they are potentially causal factors (such as injecting drug
use or blood transfusion) or just reﬂect associations with HCV
infection (such as age or socioeconomic status).
We extracted from the retrieved articles of the systematic
searches only risk factors determined to be statistically signiﬁcant
through multivariable regression analysesdthat is, after control-
ling for potential confounding factors. These risk factors were
subsequently used to populate the HCV risk factors subdatabase
indicated previously.
The extracted risk factors were classiﬁed into two categories:
key associations and modes of exposure. A key association was
deﬁned as a characteristic associated with being infected with HCV
(such as age or socioeconomic status), but is not amode of exposure
(or transmission). A mode of exposure was deﬁned as an exposure
factor that was potentially responsible for acquiring HCV infection
(such as injecting drug use or blood transfusion). Conceptual maps
by type of risk factors were developed based on the identiﬁed risk
factors in the systematic searches.
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All reported risk factors that met the deﬁnition of a key asso-
ciation were included in the conceptual map for the key associa-
tions. Similarly, all reported risk factors that met the deﬁnition of a
mode of exposure were included in the conceptual map for the
modes of exposure, and were further categorized into health
careerelated exposures, injecting drug useerelated exposures,
community-related exposures, and sexual-related exposures, based
on the type of risk factor.
Results
Scope of evidence
Table 1 lists (by country) the number of articles reporting sta-
tistically signiﬁcant risk factors after adjustment for confounders.
Risk factor data were available for 14 of the 24 MENA countries, 11
of which had less than ﬁve articles reporting risk factor informa-
tion. Egypt had the largest number of articles (n ¼ 53), followed by
Iran (n¼ 26) and Pakistan (n¼ 11). In the 109 articles reporting risk
factors, a total of 329 risk factors were identiﬁed.
Conceptual mapping of risk factors
Figure 1 provides a conceptual mapping of the key associations
with HCV infection as discerned from the extracted risk factors.
Diverse associations have been identiﬁed that range from basic
sociodemographic attributes, to occupational or incarceration
contexts, to other infection or disease status conditions.
Figure 2 provides a conceptual mapping of HCV modes of
exposure as discerned from the extracted risk factors. Three main
settings of exposure have been identiﬁed for HCV infection in
MENA: health careerelated exposures, exposures related to
injecting drug use, and community-related exposures. A fourth
setting, although limited in extent, was also identiﬁed: sexual
exposures.Within each of these settings, different speciﬁcmodes of
exposure to HCV infection or associated factors were identiﬁed.
Key associations
Table 2 reports the frequency of reported key associations in
MENA. A total of 114 key associations were reported, that is, 34.7%
of all occasions in which a risk factor was reported.
Age was by far the most reported key associationdit was
reported in 39 studies, comprising 34.2% of all occasions in which a
key association was reported. Following age was the category of
other infections or diseasesdit was reported in 20 studies,
comprising 17.5% of occasions. This category included conditions
such as diabetes, malaria, jaundice, and HIV, among others. Next
was the category of an incarceration contextdit was reported in 17
studies, comprising 14.9% of occasions. Other notable reported key
associations included: sex, education, marital status, socioeco-
nomic status, rural versus urban location, and speciﬁc geographical
regions.
Modes of exposure
Table 3 reports the frequency of reported modes of exposure in
MENA, comprising 65.3% of all reported risk factors.
Table 1
Number of articles reporting individual-level risk factors for incident HCV infection
(in prospective or retrospective incidence studies) or individual-level factors asso-
ciatedwith being infectedwith HCV infection (in cross-sectional studies of prevalent
HCV infections) in the Middle East and North Africa (MENA)
Country Number of articles
reporting risk factors
Egypt 53
Iran 26
Pakistan 11
Iraq 3
Libya 3
Morocco 2
Saudi Arabia 2
Tunisia 2
Yemen 2
Afghanistan 1
Kuwait 1
Qatar 1
Sudan 1
Syria 1
Middle East and North Africa 109
Fig. 1. Conceptual mapping of the key associations with HCV infection as discerned from the extracted risk factors. A key association is deﬁned as a characteristic associated with
being infected with HCV, but is not a mode of exposure (or transmission).
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Health careerelated exposures
HCV infection was often associated with health careerelated
exposures, comprising over half of the reported modes of expo-
sure (59.5%). Blood transfusion was the most commonly reported
mode of exposuredit was reported in 32 studies comprising 14.9%
of occasions in which a mode of exposure was reported. Parenteral
antischistosomal therapy (PAT) was second (24 studies; 11.2% of
occasions) and all of these studies were strictly from Egypt. He-
modialysis was next, where it was reported in 21 studies,
comprising 9.8% of occasions. This was followed by surgical and
other medical procedures (16 studies; 7.4% of occasions), dental
work (10 studies; 4.7% of occasions), and medical injections (9
studies; 4.2% of occasions). Other notable health careerelated ex-
posures included: health care workererelated exposures, hospi-
talization, and obstetrical care.
Exposures related to injecting drug use
Exposures (and associated factors) related to injecting drug use
comprised 20.9% of all reported modes of exposure. History of
injecting drug use was the most commonly reported factor (17
studies; 7.9% of occasions), followed by sharing of needles or sy-
ringes (11 studies; 5.1% of occasions), and duration of injecting drug
use (6 studies; 2.8% of occasions).
Community-related exposures
Community-related exposures comprised 15.8% of all reported
modes of exposure. Tattooing was the most commonly reported
risk factor (10 studies; 4.7% of occasions), followed by household
contacts of HCV-infected patients (7 studies; 3.3% of occasions), and
informal health care practices, including cupping, male circumci-
sion, and female genital mutilation (5 studies; 2.3% of occasions).
Other notable community-related exposures included: mother-to-
child transmission (4 studies; 1.9% of occasions), and exposures at
barbershops (4 studies; 1.9% of occasions).
Sexual exposures
Sexual exposures were the least frequently reported modes of
exposure (3.7%), among which, multiple sex partners (3 studies;
1.4% of occasions) was the most commonly reported risk factor.
Discussion
We presented a comprehensive mapping of HCV key associa-
tions and modes of exposure in MENA, to our knowledge the ﬁrst
such comprehensive and systematic analysis of the key associations
and modes of exposure for any world region. Our results demon-
strate that there are three key “collective clusters” of HCV expo-
sures in MENA. The ﬁrst relates to health care, which given the
aforementioned results, appears to be the primary driver of
prevalent (and possibly incident) infections. The second cluster
relates to injecting drug use, whereas the third relates to
community-related exposures. Despite some suggestive evidence
for sexual-related exposures, these appear to play a minimal role.
All identiﬁedmodes of exposure conﬁrm our overall understanding
of HCV epidemiologydno unusual modes of exposure were iden-
tiﬁed in our study.
These results highlight the role that health care has played in the
HCV epidemic in MENA, leading to this region being the most
affected by HCV infection worldwide [2]. They also conﬁrm our
understanding of HCV epidemiology in this region, as delineated
recently through a series of systematic reviews of HCV antibody
prevalence [5e14]. Indeed, the pattern of HCV antibody prevalence
in these studies mirrored closely that of the pattern of HCV risk
factors, as analyzed in the present study. These ﬁndings testify to
the need for expansion of HCV prevention in MENA through proper
Fig. 2. Conceptual mapping of HCV modes of exposure as discerned from the extracted risk factors. A mode of exposure is deﬁned as an exposure factor that was potentially
responsible for acquiring HCV infection. PWID, people who inject drugs; STD, sexually transmitted disease.
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Table 2
Frequency of reported statistically signiﬁcant key associations with hepatitis C virus (HCV) infection
Key associations Reported effect nature and direction Frequency Proportion of occasions in
which this key association
was reported
References
Age Increased age associated with higher OR 39 34.2% [38e74]
Other infections and diseases Other infections and diseases associated with higher OR 20 17.5% [44,51,56,61,63,70,73,75e79]
Incarceration Incarceration and risk factors associated with incarceration
associated with higher OR
17 14.9% [40,47,54,78,80e91]
Sex Male (n ¼ 6), female (n ¼ 2), and unspeciﬁed sex (n ¼ 2),
associated with higher OR
10 8.8% [45,59,61,74,75,82,84,87,92,93]
Education Less education associated with higher OR 6 5.3%
Marital status Single, divorced, and widowed associated with higher OR 6 5.3% [56,59,73,74,82,85]
Rural location Rural residence associated with higher OR 5 4.4% [45,56,59,94,95]
Region Speciﬁc regions associated with higher OR 4 3.5% [87,95,96]
Occupation Speciﬁc occupations associated with higher OR 1 0.9% [47,53]
Urban location Urban residence associated with higher OR 2 1.8%
Socioeconomic status Lower socioeconomic status associated with higher OR 2 1.8%
Homeless Being homeless associated with higher OR 1 0.9%
Cigarette smoking Cigarette smoking associated with higher OR 1 0.9% [86]
Total 114 100%
OR, odds ratio.
A key association is deﬁned as a characteristic associated with being infected with HCV, but is not a mode of exposure (or transmission).
Table 3
Frequency of reported statistically signiﬁcant modes of exposure for hepatitis C virus (HCV) infection
Modes of exposure
broad category
Modes of exposure
speciﬁc category
Number of studies
reporting the mode
of exposure
Proportion of
occasions in which
this mode of
exposure was
reported
Proportion of
occasions in which
this mode of exposure
was reported within
its broad category
References
Health careerelated
exposures
Blood transfusions 32 14.9% 25.0% [41,45,46,50e53,55,56,58,64,66,67,69,
73,79,86,93,94,97e107]
Parenteral antischistosomal
therapy (PAT)
24 11.2% 18.8% [43,53,55,56,59e64,67,68,70,101,
102,105,108e113]
Hemodialysis 21 9.8% 16.4% [41,52,77,92,100,106,107,114e125]
Surgical and other medical
procedures
16 7.4% 12.5% [45,46,56e58,64,69,71,77,92,93,
101,103,112,126,127]
Dental work 10 4.7% 7.8% [44,54,56,58,63,79,98,101,127,128]
Medical injections 9 4.2% 7.0% [44,69,95,101,103,128,129]
Health care workererelated
exposures
6 2.8% 4.7% [41,49,56,69,130]
Hospitalization 4 1.9% 3.1% [56,73,103,117]
Obstetrical care 4 1.9% 3.1% [98,101,130,131]
Having thalassemia 2 0.9% 1.6% [83]
Total within category 128 59.5% 100%
Injecting drug use
exposures
History of injecting drug use 17 7.9% 37.8% [40,45e49,54,56,69,73,75,76,
86,87,90,132]
Sharing needles or syringes 11 5.1% 24.4% [38,45,56,64,81,82,84,88,91,133,134]
Duration of drug use 6 2.8% 13.3% [38,78,82,84,91,135]
Frequency of injections 3 1.4% 6.7% [38,82,91]
Other injecting drug use related
exposures
8 3.7% 17.8% [38,39,46,80,89,96,135]
Total within category 45 20.9% 100%
Community-related
exposures
Tattooing 10 4.7% 29.4% [40,54,56,78,80,88,90,97,126]
Household contacts of
HCV infected patients
7 3.3% 20.6% [55,66,86,111,118,127,136]
Informal health care 5 2.3% 14.7% [56,65,79,97,111]
At barbershop 4 1.9% 11.8% [57,61,64,135]
Mother-to-child 4 1.9% 11.8% [137e140]
Other community exposures 4 1.9% 11.8% [56,75,78]
Total within category 34 15.8% 100.0
Sexual-related
exposures
Multiple sex partners 3 1.4% 37.5% [55,126,141]
Other sexual exposures 5 2.3% 62.5% [46,75,96,134]
Total within category 8 3.7% 100%
Total 215 100.0% 100%
A mode of exposure is deﬁned as an exposure factor that was potentially responsible for acquiring HCV infection.
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and universal implementation of blood safety, injection safety, and
infection control programs. They also inform the expansion of HCV
screening and direct-acting antivirals treatment programs, by tar-
geting the individual-level key associations and modes of exposure
as delineated in the present study.
A main highlight of our study is that very speciﬁc health care
exposures were repeatedly identiﬁed as risk factors, namely blood
transfusion and hemodialysis. This may suggest that these expo-
sures contribute more than previously thought to HCV incidence
in the population, and therefore, even limited rollout of in-
terventions focused on such speciﬁc exposures may result in
substantial decline in HCV incidence. This seems to be supported
by the large decline in HCV incidence observed in the United
States immediately after the introduction of blood screening and
other basic measures after identiﬁcation of the virus [142]. Na-
tional governments of resource-limited countries could focus
initially on HCV prevention through blood safety and proper
infection control in hemodialysis as a ﬁrst step to advance the
broader agenda of HCV prevention. Ultimately, although, with the
evidence for a broad range of health care exposures contributing
to HCV infection transmission, such as medical injections and
dental work (Table 3), all different health careerelated modes of
exposure need be addressed.
The role that blood transfusion plays in HCV exposures
should not be surprising in context of continued concerns about
blood safety in MENA [143]. Fragmented blood transfusion
services, inappropriate clinical use of blood and blood products,
and use of low-cost low-sensitivity screening kits have been
observed in several MENA countries [143], such as in Pakistan,
which has one of the largest HCV epidemics worldwide [30].
Establishing a centralized blood transfusion service, such as in
Iran, may markedly improve accessibility to safe blood and
blood products [143].
Similarly, the role of medical injections in HCV exposures should
not be surprising given that this region has the highest rate of
medical injections of all regions, at 4.3 per person per year
[144,145]. A large proportion of these medical injections are
administered unnecessarily, based on patients' perception that
injectable medications are more effective than other types of
equally effective therapies [146,147]. It is critical for MENA coun-
tries to ensure safe injection practices and to adopt the new World
Health Organization guidelines for the use of safety-engineered
syringes [148e150].
Our results highlight that exposures related to injecting drug
use are a main driver of HCV infection in MENA, similar to that
observed globally [151]. However, unlike many developed coun-
tries such as the United States where injecting drug use is the main
driver of HCV incidence [27,152], the role of this cluster of expo-
sures appears second to that of health care in MENA. This should
not distract from the fact that injecting drug use is a major source of
exposures that needs to be addressed urgentlywith harm reduction
services, given the scale of this practice in this region [153].
Although seven MENA countries have implemented needle/syringe
exchange programs, their coverage remains limited, apart from
Iran, where successful needle and syringe programs have been
operational for over a decade [151,154].
Although less frequently, HCV transmission has been linked to
unsafe practices in the community, particularly those including the
use/reuse of unsterile needles/syringes and contaminated sharp
objects (Table 3). Among the frequently reported community-
related exposures are tattooing, engagement in informal health
care practices (such as cupping, male circumcision, and female
genital mutilation), and using services at a barbershop. Opportu-
nities for reducing these exposures, or reducing the risk of exposure
through them, should be explored.
Among the key associations identiﬁed in this study, age was
most commonly reported. This afﬁrms the strong association be-
tween age and HCV infection, reﬂecting age as a proxy for the cu-
mulative risk of exposure, and possibly suggesting that the
likelihood of exposure could be age dependentdsay more en-
counters with health care with older age. Another key association
was incarceration. Incarcerated populations may engage in various
high risk behaviors (before or during incarceration), such as
injecting drug use, tattooing, and unprotected anal sex [155].
Although age and incarceration were common key associations
across the region, other identiﬁed key associations appear to be
location-dependent reﬂecting the nature of the HCV epidemics in
individual countries, or in subnational units of these countries.
Rural residence, for example, is a risk factor for HCV infection in
Egypt [5,156], but may not be so in other countries. The sex effect
(male vs. female) may vary also in nature and strength across the
region. This is demonstrated in Table 1 where although most
studies reported an association between male sex and HCV infec-
tion, several other studies reported that but for female sex. These
variations across the region extend also to some of the modes of
exposure. PAT, in particular, appears to be a mode of exposure but
only in Egypt, conﬁrming the link between mass PAT campaigns
and the HCV epidemic in Egypt [157,158].
This study has limitations. Although we aimed to provide a
regional picture of HCV key associations and modes of exposure,
there is large heterogeneity in availability of evidence. Few coun-
tries, such as Egypt and Iran, contributed multiple studies, whereas
no studies were available for 10 MENA countries. This may limit the
generalizability of the identiﬁed key associations and modes of
exposures to countries with limited data. Relatively small number
of studies were identiﬁed from Pakistan (only 11), although
Pakistan is enduring a large epidemic with an HCV antibody
prevalence of about 5% and over six million chronically infected
individuals [14,30]. Unlike Egypt whose epidemic, drivers, and
modes of exposure are relatively well understood [5,6,29,159,160],
the nature of HCV transmission in this country remains poorly
understooddthis highlights the need for analytical epidemiologic
studies in Pakistan to assess the speciﬁc modes of exposure and
their relative role.
Another limitation of our study is that we used citation fre-
quency to indicate the signiﬁcance of the key associations and
modes of exposures in the population, but citation frequency may
not necessarily reﬂect the actual distribution of key associations
and modes of exposures in the wider infected populationdbeyond
the studied populations included in the present analysis. Further-
more, this delineation of key associations and modes of exposure
may relate more to prevalence, rather than current incidence of
infection. For example, blood safety and infection control appear to
have improved markedly in recent years in multiple MENA coun-
tries [28,143,161]. Prevalent infections may therefore reﬂect de-
cade's old HCV exposures not representative of current
exposuresdthe relative role of health care may have decreased but
the role of injecting drug usemay have increased. Further analytical
epidemiologic studies, as well as viral hepatitis surveillance [162],
are needed to determine current trends, particularly with a focus
on incident infections.
About 400,000 newHCV infections are occurring inMENA every
year [2], stressing the need to implement effective preventative
strategies targeting the main clusters of exposure. Health care and
injecting drug use appear to be the main drivers of the HCV
epidemic in MENA, along with a smaller contribution from
community-related exposures. Commitment to HCV prevention
should be an integral component of HCV response to achieve HCV
elimination by 2030. This commitment should entail expansion and
quality assurance of blood and injection safety and infection control
S. Mahmud et al. / Annals of Epidemiology 28 (2018) 452e461 457
programs, as well as harm reduction for people who inject drugs
and in prisons.
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